What is TXMD's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TXMD?

P/E (TTM) is n/a and 52-week range is $1.11 to $2.95 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TXMD figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TXMD?

The company profile lists revenue (TTM) near $3M, net income (TTM) near -$22M, EPS (TTM) near -$0.02 when available from the market-data feed. Figures are informational and may lag live markets.

Where is TherapeuticsMD Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boca Raton, Florida, US, 11.6M shares outstanding, ISIN US88338N2062 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

TherapeuticsMD Inc

$TXMD

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

TherapeuticsMD, Inc. operates as a pharmaceutical company. The company is headquartered in Boca Raton, Florida and currently employs 1 full-time employees. The company went IPO on 2001-01-31. The company receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

Employees

Website

www.therapeuticsmd.com/

IPO

2001-01-31

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US88338N2062

Headquarters

Boca Raton, Florida, US

Shares outstanding

11.6M

NAICS sector

Manufacturing

Institutional ownership

31.72%

Browse other companiesFree AI scores and summaries for more stocks